Cancer Antigen 125 Test

CA-125 (cancer antigen 125), is a high-molecular-weight glycoprotein found on the surface of certain cells, particularly those derived from coelomic and müllerian epithelia. This includes tissues lining the ovaries, fallopian tubes, uterus, peritoneum, pleura (lung lining), and pericardium (heart lining). It is encoded by the MUC16 gene and is shed into the bloodstream when these tissues become irritated, inflamed, or cancerous.

CA-125 is best known as a tumor marker in epithelial ovarian cancer (EOC), where its levels often rise as the disease progresses. However, its usefulness is nuanced. While CA-125 is elevated in over 80% of advanced-stage EOC cases, it is much less sensitive in early-stage disease and in certain tumor subtypes like mucinous or clear cell ovarian cancers. Moreover, CA-125 lacks specificity: levels can also increase in benign conditions such as endometriosis, menstruation, uterine fibroids, and pelvic inflammatory disease, as well as during pregnancy, in heart failure, and with peritoneal inflammation. This overlap limits its reliability as a diagnostic tool on its own, especially in premenopausal women.

Clinically, CA-125 is primarily used to monitor disease status in women with a known ovarian cancer diagnosis. For example, rising levels during or after treatment may suggest cancer recurrence, while falling levels often indicate a favorable response to therapy. The Gynecologic Cancer Intergroup defines a meaningful treatment response as a 50% reduction in CA-125 levels from baseline, sustained over at least 20 days. In patients who achieve remission, CA-125 often rises before clinical or radiographic signs of recurrence, providing an early alert to oncologists.

Interestingly, recent research has also linked CA-125 to non-gynecologic conditions. For example, levels may correlate with heart failure severity and can sometimes be used alongside other tests for diagnosing ectopic pregnancy. This wider relevance stems from CA-125’s origin in mesothelial surfaces, which become activated or damaged in many disease states.

Pathophysiologically, CA-125 may play a role in immune evasion by tumors. It can bind to mesothelin, a protein on mesothelial cells, potentially facilitating cancer spread within the abdominal cavity. It may also interfere with the function of natural killer cells, which are part of the immune system’s first line of defense against tumors. These properties make CA-125 not just a passive biomarker but a potential therapeutic target in ovarian cancer.

Despite its limitations in early detection, CA-125 remains an invaluable tool in ovarian cancer management. It helps guide treatment decisions, assess prognosis, and track disease activity. Its predictive power improves when used alongside imaging and other biomarkers, such as HE4, or as part of risk-scoring systems like the Risk of Malignancy Index.